Lessons from the skin-cutaneous features of familial cancer

The Lancet Oncology

Volumn 9, Issue 5, 2008, Pages 462-472

  Winship, Ingrid M ^a   Dudding, Tracy E ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Clinical Governance Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTRONE; FUMARATE HYDRATASE; MISMATCH REPAIR PROTEIN PMS2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN PATCHED; PROTEIN RET; TUBERIN; TUMOR SUPPRESSOR PROTEIN;

ANAMNESIS; AUTOSOMAL DOMINANT INHERITANCE; BASAL CELL NEVUS SYNDROME; BIRT HOGG DUBE SYNDROME; BRAIN CANCER; BREAST CANCER; CANCER CENTER; CANCER SUSCEPTIBILITY; CARNEY COMPLEX; CLINICAL EXAMINATION; CLINICAL FEATURE; COLON POLYPOSIS; COLORECTAL CANCER; COWDEN SYNDROME; DISEASE SURVEILLANCE; ENDOMETRIUM CANCER; FAMILIAL CANCER; FAMILY HISTORY; GARDNER SYNDROME; GENE MUTATION; GENETIC ANALYSIS; HAMARTOMA; HEREDITY; HOMOZYGOSITY; HUMAN; INTESTINE CANCER; KIDNEY CANCER; KIDNEY CARCINOMA; LEIOMYOMATOSIS; MEDICAL SPECIALIST; MUIR TORRE SYNDROME; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; ONSET AGE; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PATIENT REFERRAL; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; REVIEW; SIPPLE SYNDROME; SKIN DEFECT; SMALL INTESTINE CANCER; STOMACH CANCER; TUBEROUS SCLEROSIS;

ADENOMATOUS POLYPOSIS COLI; BASAL CELL NEVUS SYNDROME; CARCINOMA, RENAL CELL; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DISEASE PROGRESSION; ENDOCRINE GLAND NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC SCREENING; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; KIDNEY NEOPLASMS; LEIOMYOMATOSIS; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; PEDIGREE; PEUTZ-JEGHERS SYNDROME; SKIN; SKIN NEOPLASMS; TUBEROUS SCLEROSIS;

EID: 42649138270     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70126-8     Document Type: Review

References (75)

1. Somoano B., Niendorf K., and Tsao H. Hereditary cancer syndromes of the skin. Clin Dermatol 23 (2005) 85-106
2. Burgdorf W. Cancer-associated genodermatoses: a personal history. Exp Dermatol 15 (2006) 653-666
3. Tsao H. Update on familial cancer syndromes and the skin. J Am Acad Dermatol 42 (2000) 939-969
4. Ferner R. Neurofibromatosis 1 and neurofibromatosis 2: a twenty-first century perspective. Lancet Neurol 6 (2007) 340-351
5. Farndon P., Del Mastro R., Evans D., and Kilpatrick M. Location of gene for Gorlin syndrome. Lancet 339 (1992) 581-582
6. Shanley S., Ratcliffe J., Hockey A., et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet 50 (1994) 282-290
7. Bale A., Gailani M., and Leffell D. The Gorlin syndrome gene: a tumor suppressor active in basal cell carcinogenesis and embryonic development. Proc Assoc Am Physicians 107 (1995) 253-257
8. Ragge N., Salt A., Collin J., Michalski A., and Farndon P. Gorlin syndrome: the PTCH gene links ocular developmental defects and tumour formation. Br J Ophthalmol 89 (2005) 988-991
9. Evans D., Ladusans E., Rimmer S., Burnell L., Thakker N., and Farndon P. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 30 (1993) 460-464
10. Kimonis V., Goldstein A., Pastakia B., et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 69 (1997) 299-308
11. Evans D., Farndon P., Burnell L., Gattamaneni H., and Birch J. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 64 (1991) 959-961
12. Cowan R., Hoban P., Kelsey A., Birch J., Gattamaneni R., and Evans D. The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer 76 (1997) 141-145
13. Lynch H., and de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 348 (2003) 919-932
14. Park J., Vasen H., Park K., et al. Suspected hereditary nonpolyposis colorectal cancer: International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) criteria and results of genetic diagnosis. Dis Colon Rectum 42 (1999) 710-715
15. Umar A., Boland C., Terdiman J., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 (2004) 261-268
16. Bigas M.R., Boland C., Hamilton S., et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome; meeting highlights and Bethesda Guidelines. J Natl Cancer Inst 89 (1997) 1758-1762
17. Hendriks Y., de Jong A., Morreau H., et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 56 (2006) 213-225
18. Schwartz R., and Torre D. The Muir Torre Syndrome: a 25-year retrospect. J Am Acad Dermatol 33 (1995) 90-104
19. Ponti G., Losi L., Pedroni M., et al. Value of MLH1 and MSH2 mutations in the appearance of Muir Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumours or keratoacanthomas. J Invest Dermatol 126 (2006) 2302-2307
20. De Vos M., Hayward B., Picton S., et al. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 74 (2004) 954-964
21. Bandipalliam P. Syndrome of early onset colon cancers, hematologic malignancies and features of neurofibromatosis in HNPCC families with homozygous mismatch repair mutations. Fam Cancer 4 (2005) 323-333
22. Scott R., Mansour S., Jones K.P., et al. Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol 4 (2007) 130-134
23. Bisgaard M., Fenger K., Bulow S., et al. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3 (1994) 121-125
24. Gardner E., and Richards R. Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am J Hum Genet 5 (1953) 139-147
25. Wallis Y., Morton D., McKeown C., et al. Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 36 (1999) 14-20
26. Pujol R., Casanova J., Egido R., et al. Multiple familial pilomatricomas: a cutaneous marker for Gardner syndrome?. Pediatr Dermatol 12 (1995) 331-335
27. Bell B., and Mazzaferri E. Familial adenomatous polyposis (Gardner's syndrome) and thyroid carcinoma. A case report and review of the literature. Dig Dis Sci 38 (1993) 185-190
28. Jenne D., Reimann H., Nezu J., et al. Peutz Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18 (1998) 38-43
29. Tomlinson I., and Houlston R. Petuz-Jeghers syndrome. J Med Genet 34 (1997) 1007-1011
30. Giardiello F., Brensinger J., Tersmette A., et al. Very high risk of cancer in Peutz Jeghers syndrome. Gastroenterology 119 (2000) 1447-1453
31. Giardiello F., and Trimbath J. Peutz Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 4 (2006) 408-415
32. Schmidt L., Warren M., Nickerson M., et al. Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 69 (2001) 876-882
33. Toro J., Glenn G., Duray P., et al. Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 135 (1999) 1195-1202
34. Choyke P. Imaging of hereditary renal cancer. Radiol Clin North Am 41 (2003) 1037-1051
35. Pavlovich C., Grubb III R., Hurley K., et al. Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 173 (2005) 1482-1486
36. Pavlovich C., Walther M., Eyler R., et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 26 (2002) 1542-1552
37. Khoo S., Giraud S., Kahnoski K., et al. Clinical and genetic studies of Birt-Hogg-Dube syndrome. J Med Genet 39 (2002) 906-912
38. Launonen V., Vierimaa O., Kiuru M., et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98 (2001) 3387-3392
39. Kiuru M., Launonen V., Hietala M., et al. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol 159 (2001) 825-829
40. Tomlinson I., Alam N., Rowan A., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30 (2002) 406-410
41. Alam N., Barclay E., Rowan A., et al. Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. Arch Dermatol 141 (2005) 199-206
42. Toro J., Nickerson M., Wei M., et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 73 (2003) 95-106
43. Alam N., Rowan A., Wortham N., et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 12 (2003) 1241-1252
44. Kiuru M., Lehtonen R., Eerola H., et al. No germline FH mutations in familial breast cancer patients. Eur J Hum Genet 13 (2005) 506-509
45. Devlin L., Shepherd C., Crawford H., and Morrison P. Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland. Dev Med Child Neurol 48 (2006) 495-499
46. O'Callaghan F., Noakes M., Martyn C., et al. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 94 (2004) 853-857
47. Roach E., and Sparagana S. Diagnosis of tuberous sclerosis complex. J Child Neurol 19 (2004) 643-649
48. Crino P., Nathanson K., and Henske E. The tuberous sclerosis complex. N Engl J Med 355 (2006) 1345-1356
49. Jones A., Shyamsundar M., Thomas M., et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 64 (1999) 1305-1315
50. Ewalt D., Sheffield E., Sparagana S., et al. Renal lesion growth in children with tuberous sclerosis complex. J Urol 160 (1998) 141-145
51. Henske E. The genetic basis of kidney cancer: why is tuberous sclerosis complex often overlooked?. Curr Mol Med 4 (2004) 825-831
52. Bjornsson J., Short M., Kwiatkowski D., et al. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 149 (1996) 1201-1208
53. Jabbour S., Davidovici B., and Wolf R. Rare syndromes. Clin Dermatol 24 (2006) 299-316
54. Carney J. Familial multiple endocrine neoplasia: the first 100 years. Am J Surg Pathol 29 (2005) 254-274
55. Asgharian B., Turner M., Gibril F., et al. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 89 (2004) 5328-5336
56. Darling T., Skarulis M., Steinberg S., Marx S., Spiegel A., and Turner M. Multiple facial angiomas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 133 (1997) 853-857
57. Brandi M., Gagel R., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001) 5658-5671
58. Verga U., Fugazzola L., Cambiaghi S., et al. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol 59 (2003) 156-161
59. Utiger R. Medullary thyroid cancer, genes and the prevention of cancer. N Engl J Med 331 (1994) 870-871
60. O'Riordain D., O'Brien T., Crotty T., et al. Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 118 (1995) 936-942
61. Stratakis C., Kirschener L., and Carney J. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 86 (2001) 4041-4046
62. Eng C. PTEN: one gene many syndromes. Hum Mutat 22 (2003) 183-198
63. Marsh D., Kum J., and Lunetta K. PTEN mutation spectrum and genotype phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggests a single entity with Cowden syndrome. Hum Mol Genet 8 (1999) 1461-1472
64. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 37 (2000) 828-830
65. Starink T., van der Veen J., Arwert F., et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 29 (1986) 222-233
66. Fackenthal J., Marsh D., Richardson A., et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 38 (2001) 159-164
67. Rhodes A., Silverman R., Harrist T., and Perez-Atayde A. Mucocutaneous lentigines, cardiomucocutaneous myxomas, and multiple blue nevi: the "LAMB" syndrome. J Am Acad Dermatol 10 (1984) 72-82
68. Atherton D., Pitcher D., Wells R., et al. A syndrome of various cutaneous pigmented lesions, myxoid neurofibromata and atrial myxoma: the NAME syndrome. Br J Dermatol 103 (1980) 421-429
69. Stratakis C., Kirschner L., and Carney J. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 86 (2001) 4041-4046
70. Stratakis C., Carney J., Lin J., et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome: analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest 97 (1996) 699-705
71. Kennedy R., Waller R., and Carney J. Ocular pigmented spots and eyelid myxomas. Am J Ophthalmol 104 (1987) 533-538
72. Boikos S., and Stratakis C. Carney complex: the first 20 years. Curr Opin Oncol 19 (2007) 24-29
73. Edwards A., Bermudez C., Piwonka G., et al. Carney's syndrome: complex myxomas. Report of four cases and review of the literature. Cardiovasc Surg 10 (2002) 264-275
74. Carney J., and Stratakis C. Epithelioid blue nevus and psammomatous melanotic schwannoma: the unusual pigmented skin tumors of the Carney complex. Semin Diagn Pathol 15 (1998) 216-224
75. Evans D., Sainio M., and Baser M. Neurofibromatosis type 2. J Med Genet 37 (2000) 897-904